会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 94. 发明授权
    • Elevation of HDL cholesterol by
2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates
    • 2 - [(氨基硫代甲基) - 肼基] -2-芳基乙基氨基甲酸酯升高HDL胆固醇
    • US5968975A
    • 1999-10-19
    • US96091
    • 1998-06-11
    • Thomas Joseph CommonsSusan Christman
    • Thomas Joseph CommonsSusan Christman
    • C07C337/08C07C255/27A61K31/27C07C271/10
    • C07C337/08
    • This invention relates to the treatment of atherosclerosis via raising the level of HDL cholesterol by administration of a compound of the formula ##STR1## wherein: R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.0-6 Ph where Ph is phenyl optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH;R.sup.4 and R.sup.5 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, or --(CH.sub.2).sub.0-6 Ar.sup.1 where Ar.sup.1 is phenyl, naphthyl, furanyl, pyridinyl or thienyl and Ar.sup.1 can be optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, phenyl, C.sub.1 -C.sub.6 alkoxy, phenoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH; andAr is phenyl, naphthyl, furanyl, pyridinyl or thienyl or Ar is optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, C.sub.1 -C.sub.6 alkoxy, phenoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH.
    • 本发明涉及通过施用下式化合物来提高HDL胆固醇水平来治疗动脉粥样硬化:其中:R1,R2和R3独立地是氢,C1-C6烷基或 - (CH2)0-6Ph,其中Ph是 任选被卤素,氰基,硝基,C 1 -C 6烷基,C 1 -C 6烷氧基,三氟甲基,C 1 -C 6烷氧基羰基,-CO 2 H或OH取代的苯基; R 4和R 5独立地是氢,C 1 -C 6烷基,C 3 -C 8环烷基或 - (CH 2)0-6Ar 1,其中Ar 1是苯基,萘基,呋喃基,吡啶基或噻吩基,Ar 1可以任选地被卤素,氰基,硝基, C 1 -C 6烷基,苯基,C 1 -C 6烷氧基,苯氧基,三氟甲基,C 1 -C 6烷氧基羰基,-CO 2 H或OH; 氰基,硝基,C 1 -C 6烷基,C 3 -C 6环烷基,苯基,C 1 -C 6烷氧基,苯氧基,三氟甲基,C 1 -C 6烷氧基羰基,C 1 -C 6烷氧基, -CO 2 H或OH。
    • 100. 发明授权
    • Acyl compounds
    • 酰基化合物
    • US5399578A
    • 1995-03-21
    • US998755
    • 1992-12-29
    • Peter BuhlmayerFranz OstermayerTibur Schmidlin
    • Peter BuhlmayerFranz OstermayerTibur Schmidlin
    • A61K31/195A61K31/41A61K31/44A61K31/47A61K31/535A61K31/675A61P9/12C07C229/38C07C231/00C07C233/47C07C233/51C07C233/54C07C235/04C07C271/10C07C311/48C07D233/54C07D233/58C07D233/64C07D257/04C07D401/12C07D401/14C07D403/00C07D405/00C07D409/00C07F9/6524
    • C07D233/64C07C229/38C07C233/54C07D257/04C07D401/12
    • Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
    • 式(I)的化合物,其中R 1是未被取代或被卤素或羟基取代的脂族烃基,或脂环族或芳脂族烃基; X 1是CO,SO 2或-O-C(= O) - ,其中羰基的碳原子连接到式I所示的氮原子上; X2是未取代的或被羟基,羧基,氨基,胍基或脂环族或芳族基团取代的二价脂族烃基,或者是二价脂环族烃基,脂族烃基的碳原子可能另外 由二价脂族烃基桥连; R 2是羧基,如果需要,其被酯化或酰胺化,取代或未取代的氨基,如果需要,缩醛化的甲酰基,1H-四唑-5-基,吡啶基,羟基,如果需要,其醚化,S(O) mR,其中m为0,1或2,R为氢或脂族烃基,烷酰基,未取代的或N-取代的氨磺酰基或POnH 2,其中n为2或3; X3是二价脂族烃; R3是羧基,5-四唑基,SO3H,PO2H2,PO3H2或卤代烷基氨磺酰; 环A和B彼此独立地是取代或未取代的; 游离形式或盐形式可以以本身已知的方式制备,并且可以用作例如药物活性成分。